Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY E

Authors

Antonella Cianferoni (ORCID: https://orcid.org/0000-0002-2966-2564)
Evan S. Dellon (ORCID: https://orcid.org/0000-0003-1167-1101)
Albert Jan Bredenoord (ORCID: https://orcid.org/0000-0001-5918-2062)
Juby A. Jacob‐Nara (ORCID: https://orcid.org/0000-0002-5372-8762)
Christoph Schlag (ORCID: https://orcid.org/0000-0003-3227-2724)
Tiffany Pela
Sandy R. Durrani (ORCID: https://orcid.org/0000-0001-8311-596X)
Amr Radwan (ORCID: https://orcid.org/0000-0003-1658-5229)
Changming Xia (ORCID: https://orcid.org/0000-0002-5703-5074)

Institutions

University of North Carolina at Chapel Hill (US)
Regeneron (United States) (US)
Bridgewater College (US)
University Hospital of Zurich (CH)
Sanofi (United States) (US)
Amsterdam University Medical Centers (NL)
University of Pennsylvania (US)

Publication Details

Journal: Expert Review of Gastroenterology & Hepatology
Published: 2025-02-01
DOI: https://doi.org/10.1080/17474124.2025.2461516
Citations: 4
Primary Topic: Eosinophilic Esophagitis
Type: article
Field-Weighted Citation Impact: 8.03

Funders

Sanofi
Regeneron Pharmaceuticals

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY E

Antonella Cianferoni, Evan S. Dellon, Albert Jan Bredenoord, Juby A. Jacob‐Nara et al.

Feb 1, 2025

4 citations

Expert Review of Gastroenterology & Hepatology

Eosinophilic Esophagitis

8.03

article

Dupilumab is efficacious for eosinophilic esophagitis irrespective of prior swallowed budesonide or fluticasone, or prior treatments used alongside swallowed topical corticosteroids: results from the phase 3, randomized, placebo-controlled, LIBERTY E

Antonella Cianferoni, Evan S. Dellon, Albert Jan Bredenoord, Juby A. Jacob‐Nara, Christoph Schlag, Tiffany Pela, Sandy R. Durrani, Amr Radwan, Changming Xia

February 1, 2025article en

4 citations

Abstract

No abstract available for this paper.

Expert Review of Gastroenterology & HepatologyVol. 19(2)

University of North Carolina at Chapel Hill (US), Regeneron (United States) (US), Bridgewater College (US), University Hospital of Zurich (CH), Sanofi (United States) (US), Amsterdam University Medical Centers (NL), University of Pennsylvania (US)

Sanofi, Regeneron Pharmaceuticals

Zero hunger

Openalex Percentile: Top 3%

Eosinophilic Esophagitis

8.03

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.